Gene · 3113
NIH grants1,839
NIH grants whose papers are about the gene, through NIH's grant-paper links.
181 to 200 of 1,839
Download this page as JSON| Grant | Title | HLA-DPA1 papers | Newest fiscal year |
|---|---|---|---|
| R01CA205406 | Leveraging Novel Randomized Clinical Trials of Vitamin D Supplementation in Patients with Colorectal Cancer: Impact on Survival and Anti-Tumor Immunity | 1 | 2025 |
| R01CA218285 | Immuno and Epigenetics of Hematopoietic Cell Transplantation | 1 | 2025 |
| R01CA218668 | Computational and experimental methods for scalable identification of oncogenic non-coding regions | 1 | 2025 |
| R01CA231838 | Immunogenetics of Outcomes Disparities After Allogeneic HCT | 1 | 2025 |
| R01CA238039 | Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway | 1 | 2025 |
| R01CA244576 | Overcoming ibrutinib resistance in mantle cell lymphoma | 1 | 2025 |
| R01CA245514 | The selective advantage of mismatch repair loss in colonic stem cells | 1 | 2025 |
| R01CA255240 | In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors | 1 | 2025 |
| R01CA263318 | Integration of epidemiology, pathology, immunology and outcomes in colorectal cancer | 1 | 2025 |
| R01CA264090 | Nano and biomolecular engineered technologies for neoantigen-specific T cell capture and characterization | 1 | 2025 |
| R01CA266676 | Discovering Infection-mediated Pathways of Glioma Etiology and Prognosis by Leveraging Multiplex Serology and Immunogenomics | 1 | 2025 |
| R01CA269580 | NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance | 1 | 2025 |
| R01CA271455 | Dissecting innate immune signaling in pre-leukemia evolution | 1 | 2025 |
| R01DA041931 | Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse | 1 | 2025 |
| R01DE028529 | Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCC's | 1 | 2025 |
| R01DE031928 | Initiation of immune responses to SARS COV2 in the oral cavity and upper airway | 1 | 2025 |
| R01DK078244 | Molecular Basis of Pathogenicity of IgA1-containing Immune Complexes | 1 | 2025 |
| R01DK099593 | Significance and mechanisms of hepatic ChREBPα induction via post-translational modifications in diet-induced NASH | 1 | 2025 |
| R01DK109581 | Assessment of Donor Quality for Improving Kidney Transplant Outcomes | 1 | 2025 |
| R01DK114007 | Mechanisms of alteration of gastrointestinal physiology by gut microbes | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3113/grants?page=10